DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,504 filers reported holding DANAHER CORPORATION in Q4 2019. The put-call ratio across all filers is 1.66 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $213,982 | -16.1% | 849 | -14.0% | 0.01% | -23.5% |
Q3 2022 | $255,000 | -54.9% | 987 | -55.7% | 0.02% | -43.3% |
Q2 2022 | $565,000 | -76.4% | 2,229 | -69.4% | 0.03% | -79.3% |
Q4 2021 | $2,396,000 | +611.0% | 7,282 | +558.4% | 0.14% | +663.2% |
Q3 2021 | $337,000 | -44.2% | 1,106 | -50.8% | 0.02% | -40.6% |
Q2 2021 | $604,000 | -54.2% | 2,249 | -61.6% | 0.03% | -57.3% |
Q1 2021 | $1,320,000 | +103.7% | 5,863 | +101.0% | 0.08% | +59.6% |
Q4 2020 | $648,000 | +173.4% | 2,917 | +165.2% | 0.05% | +487.5% |
Q3 2020 | $237,000 | +15.6% | 1,100 | -5.1% | 0.01% | +60.0% |
Q2 2020 | $205,000 | -22.3% | 1,159 | -39.2% | 0.01% | -28.6% |
Q1 2020 | $264,000 | -27.9% | 1,906 | -20.0% | 0.01% | +40.0% |
Q4 2019 | $366,000 | -97.5% | 2,382 | -97.6% | 0.01% | -97.1% |
Q3 2019 | $14,376,000 | +511.7% | 99,537 | +505.4% | 0.17% | +269.6% |
Q2 2019 | $2,350,000 | +285.2% | 16,441 | +255.9% | 0.05% | +283.3% |
Q1 2019 | $610,000 | +16.2% | 4,620 | -9.2% | 0.01% | +9.1% |
Q4 2018 | $525,000 | -44.7% | 5,087 | -41.8% | 0.01% | -45.0% |
Q3 2018 | $950,000 | +131.7% | 8,747 | +110.6% | 0.02% | +100.0% |
Q2 2018 | $410,000 | +6.2% | 4,153 | +5.4% | 0.01% | -9.1% |
Q1 2018 | $386,000 | -34.2% | 3,941 | -37.7% | 0.01% | -35.3% |
Q4 2017 | $587,000 | -51.6% | 6,321 | -55.3% | 0.02% | -56.4% |
Q3 2017 | $1,213,000 | +8.7% | 14,137 | +6.9% | 0.04% | +18.2% |
Q2 2017 | $1,116,000 | +212.6% | 13,221 | +216.7% | 0.03% | +230.0% |
Q1 2017 | $357,000 | -86.7% | 4,175 | -87.9% | 0.01% | -88.6% |
Q4 2016 | $2,678,000 | -88.1% | 34,400 | -84.5% | 0.09% | -76.3% |
Q2 2016 | $22,434,000 | +83.3% | 222,117 | +72.1% | 0.37% | +178.9% |
Q1 2016 | $12,242,000 | -0.2% | 129,049 | -10.3% | 0.13% | +37.1% |
Q3 2015 | $12,264,000 | +40.9% | 143,928 | +41.6% | 0.10% | +21.2% |
Q2 2015 | $8,702,000 | +580.9% | 101,667 | +575.4% | 0.08% | +700.0% |
Q1 2015 | $1,278,000 | -82.7% | 15,053 | -82.5% | 0.01% | -89.1% |
Q4 2014 | $7,394,000 | -73.2% | 86,262 | -76.3% | 0.09% | -53.5% |
Q3 2014 | $27,633,000 | -34.1% | 363,692 | -31.7% | 0.20% | -30.8% |
Q2 2014 | $41,944,000 | – | 532,758 | – | 0.29% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 263,188 | $33,896,000 | 13.46% |
WALTER & KEENAN WEALTH MANAGEMENT LLC /IN/ /ADV | 263,188 | $33,896,000 | 13.46% |
Defender Capital, LLC. | 127,230 | $17,610,000 | 12.86% |
Eos Focused Equity Management, L.P. | 53,908 | $7,461,000 | 11.12% |
CORTLAND ASSOCIATES INC/MO | 419,035 | $57,999,000 | 10.88% |
Mirova US LLC | 477,368 | $66,072,000 | 8.75% |
Pactiv General Employee Benefit Trust | 579,300 | $80,181,000 | 8.58% |
Riverstone Advisors, LLC | 57,623 | $7,976,000 | 8.07% |
Eversept Partners, LP | 233,957 | $32,419,197 | 8.06% |
Third Point | 3,570,000 | $494,124,000 | 7.88% |